# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | IHH HEALTHCARE BERHAD |
| Establishment Date | N/A |
| Headquarters Location | Kuala Lumpur, Malaysia |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | IHH Healthcare integrates advanced medical technologies and digital healthcare solutions, including pioneering Upright Photon Therapy in Asia and AI-powered diagnostic tools such as SenseCare Chest CT, Lunit INSIGHT MMG, and Annalise AI for imaging analysis. The Group has implemented a Clinical Risk Assurance Framework and a governance framework for ethical AI integration, alongside continuous clinical audits and a Clinical Governance Advisory Council to uphold clinical quality and safety. Additionally, IHH fosters innovation through initiatives like the I.GLOBE Custom Hospital Business Simulation and the IHH Research and Innovation Grant. | IHH Healthcare has invested in advanced medical technologies such as the proton beam therapy at Mount Elizabeth Novena Hospital, the first among private hospitals in Southeast Asia, and Ethos radiotherapy in Türkiye. The Group integrates artificial intelligence (AI) to improve disease diagnostics and employs digital healthcare applications including MyHealth360 for patient health management and AI-driven bill estimates. The Enterprise Risk Management (ERM) framework and a robust clinical governance framework, supported by the International Clinical Governance Advisory Council (ICGAC), underpin continuous quality improvement and risk management across its operations. |
| Product Advantages | IHH Healthcare operates a diversified portfolio of over 140 healthcare facilities, including more than 80 hospitals across 10 countries, offering a full spectrum of integrated healthcare services from primary to quaternary care, including diagnostics, laboratory testing, and rehabilitation. The Group manages well-known brands such as Acibadem, Fortis, Gleneagles, Island, Mount Elizabeth, Pantai, and Parkway, and expands offerings with advanced tests like genomics and high-end diagnostics. It also emphasizes complex care services, ambulatory care, and primary care clinic penetration in selected markets. | IHH Healthcare offers a broad portfolio of healthcare services across over 80 hospitals in 10 countries, including specialised cancer treatments like CAR T-cell therapy and minimally invasive surgeries using the da Vinci Robotic Surgical System. The Group's brands, such as Mount Elizabeth, Parkway, Gleneagles, Pantai, Fortis Healthcare, and Prince Court, provide integrated healthcare services including clinics, hospitals, laboratories, and radiology. The laboratory business is a growing segment, conducting 96 million tests across four markets in the fiscal year, with Premier Integrated Labs positioned as a reference lab. |
| Brand Recognition | IHH Healthcare is recognized as one of the world's most trusted healthcare services networks, with established brands that have strong reputations for clinical outcomes and quality care. The Group received multiple prestigious awards in 2024, including FinanceAsia Asia's Best Company Awards and Corporate Governance Asia's Asian Excellence Awards, highlighting leadership in investor relations, corporate governance, and financial management. Its brands, such as Acibadem, have received local accolades like the Brandverse Gold Award in Turkey, and the Group is acknowledged for thought leadership through platforms like the HealthcareInsider series. | IHH Healthcare is recognised as a leading private healthcare provider with strong brand presence in its markets, including awards such as 'Most Outstanding Company in Singapore - Healthcare Sector' by Asiamoney Asia and the Gold award in 'Healthcare Institutions' category at Brandverse Awards Türkiye 2023. The Group maintains long-term relationships with stakeholders and is acknowledged for leadership excellence in Institutional Investor's 2023 Asia Pacific Executive Team rankings across multiple categories. Its hospitals, such as Mount Elizabeth, are known globally for clinical outcomes and personalised service. |
| Reputation Ratings | IHH Healthcare maintains robust governance and sustainability frameworks overseen by the Board and Sustainability Committee, integrating ESG risks into enterprise risk management and aligning with IFRS S2 climate-related disclosures. The Group received the National Corporate Governance & Sustainability Awards (NACGSA) Excellence Award 2024 and is ranked in TIME's World's Best Companies 2024. It adheres to international accreditation standards such as Joint Commission International (JCI) and Malaysian Society for Quality in Health (MSQH), and promotes transparency through comprehensive investor relations policies and regular stakeholder engagement. | IHH Healthcare has received multiple ESG-related recognitions including Best ESG Reporting (Large Cap) at the IR Magazine Awards South East Asia 2023 and the Community Health Outreach Programme Award for Gleneagles Hospital Kuala Lumpur. The Group adheres to sustainability governance with a dedicated Sustainability Committee and integrates sustainability into its Balanced Scorecard linked to remuneration. It complies with international accreditation standards such as JCI, MSQH, and NABH, and actively manages ESG risks through its ERM framework with independent assurance and alignment efforts towards TCFD recommendations. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | At IHH, we are united by our shared commitment to touch lives and transform care for patients and communities worldwide. |
| Vision Statement | To be the world's most trusted healthcare services network |
| Core Values | Patients First, Integrity, Empathy, Teamwork, Excellence |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 24,383.0 | 20,935.0 | 17,988,687.0 | Millions | RM |
| Cost of Goods Sold | (6,811.0) | (5,578.0) | (5,497,553.0) | Millions | RM |
| Gross Profit | 16,572.0 | 15,357.0 | 12,491,134.0 | Millions | RM |
| Operating Expense | (15,789.0) | (13,253.0) | (10,252,020.0) | Millions | RM |
| Operating Income | 4,783.0 | 4,104.0 | 2,217,091.0 | Millions | RM |
| Net Profit | 3,162.0 | 3,391.0 | 1,645,142.0 | Millions | RM |
| Income before income taxes | 3,756.0 | 4,049.0 | 2,217,091.0 | Millions | RM |
| Income tax expense(benefit) | (594.0) | (658.0) | (571,949.0) | Millions | RM |
| Interest Expense | (1,065.0) | (941.0) | (657,413.0) | Millions | RM |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | N/A | N/A | N/A | N/A | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A |
| Non-Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | N/A | N/A | N/A | N/A | N/A |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Non-Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Shareholders' Equity | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Total Equity and Liabilities | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Prepaid Expenses | N/A | N/A | N/A | N/A | N/A |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | N/A | N/A | N/A | N/A | N/A |
| Net Cash Flow from Investing | N/A | N/A | N/A | N/A | N/A |
| Net Cash Flow from Financing | N/A | N/A | N/A | N/A | N/A |
| Net Increase/Decrease in Cash | N/A | N/A | N/A | N/A | N/A |
| Dividends | N/A | N/A | N/A | N/A | N/A |


## S2.4: Key Financial Metrics

|       | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Profit Margin | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A |
| Debt-to-Equity | N/A | N/A | N/A |
| Interest Coverage | N/A | N/A | N/A |
| Asset Turnover | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Effective Tax Rate | N/A | N/A | N/A | 
| Dividend Payout Ratio | N/A | N/A | N/A |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | N/A | N/A | N/A |
| Revenue by Geographic Region | N/A | N/A | N/A |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | N/A |
| Operating Efficiency | N/A |
| External & One-Off Impact | N/A |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | N/A | N/A |
| Profitability and earnings quality | N/A | N/A |
| Operational efficiency | N/A | N/A |
| Financial risk identification and early warning | N/A | N/A |
| Future financial performance projection | N/A | N/A |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | N/A | N/A |
| Market Position | N/A | N/A |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | N/A | N/A |
| Operational Risks | N/A | N/A |
| Financial Risks | N/A | N/A |
| Compliance Risks | N/A | N/A |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| N/A | N/A | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | N/A | N/A |
| Control activities | N/A | N/A |
| Monitoring mechanisms | N/A | N/A |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | N/A | N/A |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | N/A | N/A |
| New technologies | N/A | N/A |
| Organisational Restructuring | N/A | N/A |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | N/A | N/A |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | N/A | N/A |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | N/A |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | N/A | N/A |
